Search

Your search keyword '"Effinger, Karen E."' showing total 36 results
Start Over Author "Effinger, Karen E."
36 results on '"Effinger, Karen E."'

16. Late hepatic toxicity surveillance for survivors of childhood, adolescent and young adult cancer: Recommendations from the international late effects of childhood cancer guideline harmonization group

Author

Bardi, Edit, primary, Mulder, Renée L., additional, van Dalen, Elvira C., additional, Bhatt, Neel S., additional, Ruble, Kathy A., additional, Burgis, Jennifer, additional, Castellino, Sharon M., additional, Constine, Louis S., additional, den Hoed, Caroline M., additional, Green, Daniel M., additional, Koot, Bart G.P., additional, Levitt, Gill, additional, Szonyi, László, additional, Wallace, W. Hamish, additional, Skinner, Roderick, additional, Hudson, Melissa M., additional, Kremer, Leontien C.M., additional, Effinger, Karen E., additional, and Bresters, Dorine, additional

Published
2021
Full Text
View/download PDF

17. Additional file 1 of Patterns of surveillance for late effects of BCR-ABL tyrosine kinase inhibitors in survivors of pediatric Philadelphia chromosome positive leukemias

Author

Smith, Stephanie M., Sabnis, Himalee S., Lewis, Rebecca Williamson, Effinger, Karen E., Bergsagel, John, Patterson, Briana, Mertens, Ann, Sakamoto, Kathleen M., Schapira, Lidia, and Castellino, Sharon M.

Abstract

Additional file 1: Supplemental Table 1. Cardiac and endocrine surveillance requirements on select pediatric CML clinical trials. Supplemental Table 2. Cardiac and endocrine surveillance requirements after completion of upfront therapy on select pediatric Ph + ALL clinical trials.

Published
2021
Full Text
View/download PDF

18. Late hepatic toxicity surveillance for survivors of childhood, adolescent and young adult cancer: Recommendations from the international late effects of childhood cancer guideline harmonization group

Author

Zorg en O&O, Child Health, SCT patientenzorg, Bardi, Edit, Mulder, Renée L, van Dalen, Elvira C, Bhatt, Neel S, Ruble, Kathy A, Burgis, Jennifer, Castellino, Sharon M, Constine, Louis S, den Hoed, Caroline M, Green, Daniel M, Koot, Bart G P, Levitt, Gill, Szonyi, László, Wallace, W Hamish, Skinner, Roderick, Hudson, Melissa M, Kremer, Leontien C M, Effinger, Karen E, Bresters, Dorine, Zorg en O&O, Child Health, SCT patientenzorg, Bardi, Edit, Mulder, Renée L, van Dalen, Elvira C, Bhatt, Neel S, Ruble, Kathy A, Burgis, Jennifer, Castellino, Sharon M, Constine, Louis S, den Hoed, Caroline M, Green, Daniel M, Koot, Bart G P, Levitt, Gill, Szonyi, László, Wallace, W Hamish, Skinner, Roderick, Hudson, Melissa M, Kremer, Leontien C M, Effinger, Karen E, and Bresters, Dorine

Published
2021

27. Long-term health and social function in adult survivors of paediatric astrocytoma: A report from the Childhood Cancer Survivor Study

Author

Effinger, Karen E., primary, Stratton, Kayla L., additional, Fisher, Paul Graham, additional, Ness, Kirsten K., additional, Krull, Kevin R., additional, Oeffinger, Kevin C., additional, Armstrong, Gregory T., additional, Robison, Leslie L., additional, Hudson, Melissa M., additional, Leisenring, Wendy M., additional, and Nathan, Paul C., additional

Published
2019
Full Text
View/download PDF

28. Growth disturbances in children and adolescents receiving long‐term tyrosine kinase inhibitor therapy for Chronic Myeloid Leukaemia or Philadelphia Chromosome‐positive Acute Lymphoblastic Leukaemia

Author

Sabnis, Himalee S., primary, Keenum, Caroline, additional, Lewis, Rebecca W., additional, Patterson, Briana, additional, Bergsagel, John, additional, Effinger, Karen E., additional, Silverman, Emily, additional, Mertens, Ann C., additional, and Castellino, Sharon M., additional

Published
2018
Full Text
View/download PDF

29. Growth disturbances in children and adolescents receiving long‐term tyrosine kinase inhibitor therapy for Chronic Myeloid Leukaemia or Philadelphia Chromosome‐positive Acute Lymphoblastic Leukaemia.

Author

Sabnis, Himalee S., Keenum, Caroline, Lewis, Rebecca W., Patterson, Briana, Bergsagel, John, Effinger, Karen E., Silverman, Emily, Mertens, Ann C., and Castellino, Sharon M.

Subjects
CHRONIC myeloid leukemia, DASATINIB, PROTEIN-tyrosine kinases, GROWTH of children, ADOLESCENCE, KINASE inhibitors
Abstract

The article offers information on the long-term impact of Tyrosine kinase inhibitors (TKIs) in children either in combination therapy or over decades of continuous exposure is limited, especially their impact on growth; and mentions that TKIs have led to a paradigm shift in the treatment of children and adolescents with chronic myeloid leukaemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukaemia.

Published
2019
Full Text
View/download PDF

30. Effect of Temporal Changes in Therapeutic Exposure on Self-reported Health Status in Childhood Cancer Survivors

Author

Ness, Kirsten K., primary, Hudson, Melissa M., additional, Jones, Kendra E., additional, Leisenring, Wendy, additional, Yasui, Yutaka, additional, Chen, Yan, additional, Stovall, Marilyn, additional, Gibson, Todd M., additional, Green, Daniel M., additional, Neglia, Joseph P., additional, Henderson, Tara O., additional, Casillas, Jacqueline, additional, Ford, Jennifer S., additional, Effinger, Karen E., additional, Krull, Kevin R., additional, Armstrong, Gregory T., additional, Robison, Leslie L., additional, Oeffinger, Kevin C., additional, and Nathan, Paul C., additional

Published
2016
Full Text
View/download PDF

32. Longitudinal Evaluation Of Health Status In Aging Pediatric Hodgkin Lymphoma Survivors: Report From The Childhood Cancer Survivor Study

Author

Effinger, Karen E., primary, Leisenring, Wendy M., additional, Oeffinger, Kevin C., additional, Hudson, Melissa M., additional, Ness, Kirsten K., additional, Marina, Neyssa, additional, Stovall, Marilyn, additional, Armstrong, Gregory T., additional, Robison, Leslie L., additional, Sainani, Kristin, additional, and Whittemore, Alice S., additional

Published
2013
Full Text
View/download PDF

33. Outcomes within Five Years from Diagnosis in Pediatric Hodgkin Lymphoma Patients Following Contemporary Therapy

Author

Effinger, Karen E, Bergsagel, John, Lawrence, Taylor, Keller, Frank G, Lewis, Rebecca Williamson, Meacham, Lillian, Mertens, Ann, and Castellino, Sharon M.

Abstract

Background: Survival rates for pediatric Hodgkin lymphoma (HL) exceed 95% with contemporary therapy. To reduce long-term morbidity while maintaining excellent survival, risk-adapted therapy including tailored use of radiation has been developed. Studies of 5-year survivors and cohorts treated in the 1970s-1990s have shown pediatric HL survivors are at increased risk for treatment-related chronic health conditions, including subsequent malignancies, cardiopulmonary disease, thyroid dysfunction, and infertility. However, little is known about chronic conditions associated with contemporary therapy presenting during the first 5 years from diagnosis (early outcomes). The purpose of this study was to analyze survival and early outcomes of pediatric HL patients treated with contemporary therapy.

Published
2017
Full Text
View/download PDF

34. Growth Disturbances in Pediatric Patients Receiving Long-Term Tyrosine Kinase Inhibitor Therapy

Author

Sabnis, Himalee, Keenum, Caroline, Lewis, Rebecca Williamson, Silverman, Emily A., Patterson, Briana, Effinger, Karen E., Bergsagel, John, Mertens, Ann, and Castellino, Sharon M.

Abstract

Background:Since their approval in 2003, Tyrosine Kinase Inhibitors (TKIs) targeting bcr-abl1 kinase activity have changed the treatment paradigm for children with chronic myeloid leukemia (CML) and Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL). However, off-target inhibition of kinases, such as src and c-kit, can result in impaired osteoblast function, cause an imbalance in calcium and phosphate metabolism, and result in growth impairment in children. The aim of our study was to examine growth over time in pediatric patients receiving TKIs for CML or Ph+ ALL.

Published
2017
Full Text
View/download PDF

35. Health Knowledge in Adolescent Childhood Cancer Survivors at High Risk for Therapy-Related Cardiotoxicity.

Author

Janardan SK, Mertens AC, and Effinger KE

Abstract

Childhood cancer survivors' (CCS) knowledge about late effects can promote positive health behaviors and autonomy. Cardiotoxicity is a major source of morbidity, which can be mitigated through exercise. Descriptive and Fisher's exact statistics were used to characterize health knowledge and physical activity in CCS ≥13 years at high risk for cardiotoxicity. Of 16 CCS (mean age 17.0 ± 2.1 years), 3 (18.8%) identified previous anthracycline exposure, and 5 (31.2%) had adequate physical activity. Of survivors <18 years, 82% had poor late effects knowledge ( p = 0.005). Knowledge was not associated with physical activity ( p = 0.60). Interventions are needed to improve late effects knowledge in adolescent CCS.

Published
2024
Full Text
View/download PDF

36. Early Posttherapy Opioid Prescription, Potential Misuse, and Substance Use Disorder Among Pediatric Cancer Survivors.

Author

Ji X, Hu X, Brock KE, Mertens AC, Cummings JR, and Effinger KE

Subjects
Adolescent, Analgesics, Opioid therapeutic use, Child, Humans, Prescriptions, Survivors, Young Adult, Cancer Survivors, Neoplasms drug therapy, Neoplasms epidemiology, Opioid-Related Disorders epidemiology
Abstract

Background: Pediatric cancer survivors often have pain, which may be managed with opioids. We examined the prevalence of opioid prescriptions, potential misuse, and substance use disorders (SUDs) among pediatric cancer survivors during the first year posttherapy., Methods: Using MarketScan Commercial Database, we identified 8969 survivors (aged 21 years or younger at diagnosis) who completed cancer therapy in 2009-2018 and remained continuously enrolled for at least 1 year posttherapy and 44 845 age-, sex-, and region-matched enrollees without cancer as a comparison group. Outcomes included opioid prescriptions, any indicator of potential prescription opioid misuse, and SUDs within 1 year posttherapy. Outcomes were compared between survivors and noncancer peers in bivariate and adjusted analyses, stratified by off-therapy age (children: 0-11 years; adolescents: 12-17 years; young adults: 18-28 years). All statistical tests were 2-sided., Results: A higher proportion of survivors than noncancer peers filled opioid prescriptions (children: 12.7% vs 2.0%; adolescents: 22.9% vs 7.7%; young adults: 26.0% vs 11.9%). In models adjusting for sociodemographic factors and health status, survivors remained 74.4%-404.8% more likely than noncancer peer to fill opioid prescriptions (P < .001). The prevalence of potential misuse or SUDs was low, with 1.4% of child, 4.7% of adolescent, and 9.4% of young adult survivors fulfilling at least 1 criterion; however, it was higher than noncancer peers (0.1%, 1.4%, and 4.3%, respectively). In adjusted models, the likelihood of potential misuse among survivors remained at least 2 times higher than that among noncancer peers (P  < .001), and the difference in SUDs became nonstatistically significant., Conclusion: Statistically significantly higher rates of opioid prescriptions and potential misuse were found among pediatric cancer survivors within 1 year posttherapy as compared with peers without cancer., (© The Author(s) 2022. Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissions@oup.com.)

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results